Oral PCSK9 inhibitors: closing the gap between potency and practicality.
PURPOSE OF REVIEW Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a new generation of lipid-lowering therapies that combine the potency of injectable PCSK9 inhibitors with the convenience of oral administration. This review examines the mechanisms, trial evidence, and implementation cons...